Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Myrtle Potter & Company, a life science and healthcare advisory firm specializing in corporate strategy, product development and product commercialization, announced the company has been engaged by Esperion Therapeutics, a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia, to guide and develop the commercialization strategies for the ETC-1002 (bempedoic acid) portfolio.
Subscribe to our email newsletter
Founded in 2005 by Myrtle Potter, Myrtle Potter & Company specializes in devising novel strategies to maximize the value of prescription drug brands and portfolios.
"We have a history of working with pharmaceutical and biotech companies to maximize the commercial value of their innovative products," said Myrtle Potter, CEO.
"We are eager to couple Esperion’s lipid-regulating drug development expertise with our commercialization expertise as we work together to successfully commercialize the ETC-1002 portfolio."
Myrtle Potter & Company, founded in 2005, is a life science and healthcare advisory firm. Expertise includes business strategy, product commercialization, customer engagement, product development, business development, loss of exclusivity strategies and organization development.
With more than 30 years in the healthcare industry, Potter has built an advisory firm that brings proven and relevant experience to their clients.